+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2016-12-14Number of Pages: 222

Cancer Immunotherapy Market (Therapy Type - Monoclonal Antibodies, Immune Checkpoint Inhibitors (PD-1/PD-L1 and CTLA-4), Immune System Modulators, and Cancer Vaccines; Therapeutic Areas - Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Melanoma, and Blood Cancers; End Users - Hospitals, ASC’s (Ambulatory Surgical Centers), and Cancer Research Centers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Global Cancer Immunotherapy Market: Snapshot 

The global cancer immunotherapy market is expected to experience a very high rate of growth over the coming years, owing to the increase in the number of patients suffering from various types of cancer. In terms of the treatment options for cancer, cancer immunotherapy is expected to make serious headway due to its proven greater efficiency over conventional treatment methods. The market is also expected to show a high growth rate over the coming years due to a highly promising treatments pipeline. However, the global cancer immunotherapy market is expected to be hindered by factors such as the high level of attrition within the development cycles of its several product types, and the overall lack of awareness of immunotherapy as a better option to conventional treatment in multiple regions of the world. 

In 2015, the global cancer immunotherapy market was valued at US$37.50 bn. With its revenue expected to progress at a very strong CAGR of 14.6% within a forecast period from 2016 to 2024, the global cancer immunotherapy market is expected to reach US$124.88 bn by the end of 2024. 

cancer immunotherapy market

Monoclonal Antibodies Continue Being Top Cancer Immunotherapy

In terms of types of therapies, the global cancer immunotherapy market can be segmented into cancer vaccines, immune system modulators, immune checkpoint inhibitors, and monoclonal antibodies. Monoclonal antibodies have so far been the leading choice of treatment methods for a large portion of the global healthcare industry, giving it a high lead over other segments. This therapy type has been more affordable than the other types, allowing it to gain greater popularity. However, the global cancer immunotherapy market is expected to witness a spike in the demand for immune checkpoint inhibitors due to their greater percentages of success rates and higher overall efficiency. 

In terms of area of therapy, the global cancer immunotherapy market can be segmented into blood cancer, melanoma, prostate cancer, breast cancer, colorectal cancer, lung cancer, and other minor areas. Of these, breast cancer has been the leading area of immunotherapy. Lung cancer is also showing a very high increase in rate of demand owing to the growing population of smokers and the higher overall air pollution in urban areas. 

Developed Economies Show Higher Development Rates in Cancer Immunotherapy

From a geographical perspective, the global cancer immunotherapy market can be segmented into North America, Europe, Asia Pacific, and the rest of the world. The market’s past has more or less been written within the developed economies of the world. North America and Europe have been base for several of the top level research and development efforts in the global cancer immunotherapy market so far. Both regions have also shown a great deal of demand for cancer immunotherapy owing to a more aware population and a better overall healthcare outreach. At the same time, the growing rate of awareness in other parts of the world – especially in Asia Pacific – is expected to guide the global cancer immunotherapy market in the coming years. Asia Pacific especially shows a very highly favorable rate of growth in cancer immunotherapy adoption due to an increasing density in urban populations, growing awareness rates of common cancer types such as prostate and breast cancers, and the booming industry of medical tourism. 

The leading players that have so far been in operation within the global cancer immunotherapy market include Bristol-Myers Squibb Company, Amgen, Inc., AstraZeneca Plc., Eli Lilly and Company, GlaxoSmithKline Plc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Janssen Biotech, Inc., Pfizer, Inc., Novartis AG, Spectrum Pharmaceuticals, Inc., Sanofi, and Takeda Pharmaceuticals.

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Cancer Immunotherapy Market

4. Market Overview
     4.1. Introduction
            4.1.1. Market Definition
            4.1.2. Industry Evolution / Developments
     4.2. Overview
     4.3. Key Market Indicators
            4.3.1. Region/Country Specific
            4.3.2. Product/Therapeutic Area Specific
            4.3.3. Target Market Specific – Global Scenario
     4.4. Market Dynamics
            4.4.1. Drivers
            4.4.2. Restraints
            4.4.3. Opportunity
            4.4.4. Trends
     4.5. Global Cancer Immunotherapy Market Analysis and Forecasts, 2016–2024
            4.5.1. Market Revenue Projections (US$ Mn)
     4.6. Cancer Immunotherapy Market - Global Supply Demand Scenario
     4.7. Porter’s Five Force Analysis
     4.8. Value Chain Analysis
            4.8.1. List of active market participants
                     4.8.1.1.  Manufacturers
                     4.8.1.2.  Distributors
            4.8.2. Forward – Backward Integration Scenario
     4.9. Market Outlook
     4.10. Pipeline Snapshot
     4.11. Cancer Epidemiology
     4.12. Reimbursement Scenario and Patient Support Programs Overview

5. Global Cancer Immunotherapy Market Analysis and Forecasts, By Therapy Type
     5.1. Introduction & Definition
     5.2. Key Findings / Developments
     5.3. Market Value Forecast By Therapy Type, 2016–2024
            5.3.1. Monoclonal Antibodies
            5.3.2. Immune Checkpoint Inhibitors
                     5.3.2.1. PD-1/PD-L1
                     5.3.2.2. CTLA-4
            5.3.3. Immune System Modulators
            5.3.4. Cancer Vaccines
            5.3.5. Others
     5.4. Market Attractiveness By Therapy 

6. Global Cancer Immunotherapy Market Analysis and Forecasts, By End User 
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Market Value  Forecast By End User, 2016–2024
            6.3.1. Hospitals
            6.3.2. ASC's
            6.3.3. Cancer Research Institutes
            6.3.4. Clinics
     6.4. Market Attractiveness By End User 

7. Global Cancer Immunotherapy Market Analysis and Forecasts, By Therapeutic Area 
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Market Value  Forecast By Therapeutic Area, 2016–2024
            7.3.1. Lung Cancer
            7.3.2. Colorectal Cancer
            7.3.3. Breast Cancer
            7.3.4. Prostate Cancer
            7.3.5. Melanoma
            7.3.6. Blood Cancers
            7.3.7. Others
     7.4. Market Attractiveness By Therapeutic Area 

8. Global Cancer Immunotherapy Market Analysis and Forecasts, By Region
     8.1. Key Findings
     8.2. Policies and Regulations
     8.3. Market Value  Forecast By Region
            8.3.1. North America 
            8.3.2. Europe 
            8.3.3. Asia Pacific 
            8.3.4. Latin America 
            8.3.5. Middle East and Africa 
     8.4. Market Attractiveness By Region

9. North America Cancer Immunotherapy Market Analysis and Forecast
     9.1. Introduction
            9.1.1. Key Findings
            9.1.2. Policies and Regulations
     9.2. Market Value Forecast By Therapy Type, 2016–2024
            9.2.1. Monoclonal Antibodies
            9.2.2. Immune Checkpoint Inhibitors
                     9.2.2.1. PD-1/PD-L1
                     9.2.2.2. CTLA-4
            9.2.3. Immune System Modulators
            9.2.4. Cancer Vaccines
            9.2.5. Others
     9.3. Market Value  Forecast By End User, 2016–2024
            9.3.1. Hospitals
            9.3.2. ASC's
            9.3.3. Cancer Research Institutes
            9.3.4. Clinics
     9.4. Market Value  Forecast By Therapeutic Area, 2016–2024
            9.4.1. Lung Cancer
            9.4.2. Colorectal Cancer
            9.4.3. Breast Cancer
            9.4.4. Prostate Cancer
            9.4.5. Melanoma
            9.4.6. Blood Cancer
            9.4.7. Others
     9.5. Market Value  Forecast By Country, 2016–2024
            9.5.1. U.S.
            9.5.2. Canada
     9.6. Market Attractiveness Analysis 
            9.6.1. By Therapy Type
            9.6.2. By End User 
            9.6.3. By Therapeutic Area 
            9.6.4. By Country

10. Europe Cancer Immunotherapy Market Analysis and Forecast
     10.1.Introduction
            10.1.1. Key Findings
            10.1.2. Policies and Regulations
     10.2.Market Value  Forecast By Therapy Type, 2016–2024
            10.2.1. Monoclonal Antibodies
            10.2.2. Immune Checkpoint Inhibitors
                     10.2.2.1. PD-1/PD-L1
                     10.2.2.2. CTLA-4
            10.2.3. Immune System Modulators
            10.2.4. Cancer Vaccines
            10.2.5. Others
     10.3.Market Value  Forecast By End User, 2016–2024
            10.3.1. Hospitals
            10.3.2. ASC's
            10.3.3. Cancer Research Institutes
            10.3.4. Clinics
     10.4.Market Value  Forecast By Therapeutic Area, 2016–2024
            10.4.1. Lung Cancer
            10.4.2. Colorectal Cancer
            10.4.3. Breast Cancer
            10.4.4. Prostate Cancer
            10.4.5. Melanoma
            10.4.6. Blood Cancer
            10.4.7. Others
     10.5.Market Value  Forecast By Country, 2016–2024
            10.5.1. Germany
            10.5.2. U.K. 
            10.5.3. France
            10.5.4. Spain
            10.5.5. Italy
            10.5.6. Rest of Europe
     10.6.Market Attractiveness Analysis 
            10.6.1. By Therapy Type
            10.6.2. By End User 
            10.6.3. By Therapeutic Area 
            10.6.4. By Country

11. Asia Pacific Cancer Immunotherapy Market Analysis and Forecast
     11.1.Introduction
            11.1.1. Key Findings
            11.1.2. Policies and Regulations
     11.2.Market Value  Forecast By Therapy Type, 2016–2024
            11.2.1. Monoclonal Antibodies
            11.2.2. Immune Checkpoint Inhibitors
                     11.2.2.1. PD-1/PD-L1
                     11.2.2.2. CTLA-4
            11.2.3. Immune System Modulators
            11.2.4. Cancer Vaccines
            11.2.5. Others
     11.3.Market Value  Forecast By End User, 2016–2024
            11.3.1. Hospitals
            11.3.2. ASC's
            11.3.3. Cancer Research Institutes
            11.3.4. Clinics
     11.4.Market Value  Forecast By Therapeutic Area, 2016–2024
            11.4.1. Lung Cancer
            11.4.2. Colorectal Cancer
            11.4.3. Breast Cancer
            11.4.4. Prostate Cancer
            11.4.5. Melanoma
            11.4.6. Blood Cancer
            11.4.7. Others
     11.5.Market Value  Forecast By Country, 2016–2024
            11.5.1. Japan
            11.5.2. China
            11.5.3. India
            11.5.4. Australia
            11.5.5. New Zealand
            11.5.6. Rest of APAC
     11.6.Market Attractiveness Analysis 
            11.6.1. By Therapy Type
            11.6.2. By End User 
            11.6.3. By Therapeutic Area 
            11.6.4. By Country
12. Latin America Cancer Immunotherapy Market Analysis and Forecast
     12.1.Introduction
            12.1.1. Key Findings
            12.1.2. Policies and Regulations
     12.2.Market Value  Forecast By Therapy Type, 2016–2024
            12.2.1. Monoclonal Antibodies
            12.2.2. Immune Checkpoint Inhibitors
                     12.2.2.1. PD-1/PD-L1
                     12.2.2.2. CTLA-4
            12.2.3. Immune System Modulators
            12.2.4. Cancer Vaccines
            12.2.5. Others
     12.3.Market Value  Forecast By End User, 2016–2024
            12.3.1. Hospitals
            12.3.2. ASC's
            12.3.3. Cancer Research Institutes
            12.3.4. Clinics
     12.4.Market Value  Forecast By Therapeutic Area, 2016–2024
            12.4.1. Lung Cancer
            12.4.2. Colorectal Cancer
            12.4.3. Breast Cancer
            12.4.4. Prostate Cancer
            12.4.5. Melanoma
            12.4.6. Blood Cancer
            12.4.7. Others
     12.5.Market Value  Forecast By Country, 2016–2024
            12.5.1. Brazil
            12.5.2. Mexico
            12.5.3. Rest of Latin America
     12.6.Market Attractiveness Analysis 
            12.6.1. By Therapy Type
            12.6.2. By End User 
            12.6.3. By Therapeutic Area 
            12.6.4. By Country

13. Middle East and Africa Cancer Immunotherapy Market Analysis and Forecast
     13.1.Introduction
            13.1.1. Key Findings
            13.1.2. Policies and Regulations
     13.2.Market Value  Forecast By Therapy Type, 2016–2024
            13.2.1. Monoclonal Antibodies
            13.2.2. Immune Checkpoint Inhibitors
                     13.2.2.1. PD-1/PD-L1
                     13.2.2.2. CTLA-4
            13.2.3. Immune System Modulators
            13.2.4. Cancer Vaccines
            13.2.5. Others
     13.3.Market Value  Forecast By End User, 2016–2024
            13.3.1. Hospitals
            13.3.2. ASC's
            13.3.3. Cancer Research Institutes
            13.3.4. Clinics
     13.4.Market Value  Forecast By Therapeutic Area, 2016–2024
            13.4.1. Lung Cancer
            13.4.2. Colorectal Cancer
            13.4.3. Breast Cancer
            13.4.4. Prostate Cancer
            13.4.5. Melanoma
            13.4.6. Blood Cancer
            13.4.7. Others
     13.5.Market Value  Forecast By Country, 2016–2024
            13.5.1. Saudi Arabia
            13.5.2. UAE
            13.5.3. South Africa
            13.5.4. Rest of MEA
     13.6.Market Attractiveness Analysis 
            13.6.1. By Therapy Type
            13.6.2. By End User 
            13.6.3. By Therapeutic Area 
            13.6.4. By Country

14. Competition Landscape
     14.1.Market Player – Competition Matrix (By Tier and Size of companies)
     14.2.Market Share Analysis By Company (2015)
     14.3.Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
            14.3.1. Amgen, Inc.
                     14.3.1.1. Overview
                     14.3.1.2. Financials
                     14.3.1.3. Recent Developments
                     14.3.1.4. Strategy 
            14.3.2. AstraZenca Plc
                     14.3.2.1. Overview
                     14.3.2.2. Financials
                     14.3.2.3. Recent Developments
                     14.3.2.4. Strategy
            14.3.3. Bristol-Myers Squibb Company
                     14.3.3.1. Overview
                     14.3.3.2. Financials
                     14.3.3.3. Recent Developments
                     14.3.3.4. Strategy
            14.3.4. Eli Lilly and Company
                     14.3.4.1. Overview
                     14.3.4.2. Financials
                     14.3.4.3. Recent Developments
                     14.3.4.4. Strategy
            14.3.5. F.Hoffmann-La Roche Ltd.
                     14.3.5.1. Overview
                     14.3.5.2. Financials
                     14.3.5.3. Recent Developments
                     14.3.5.4. Strategy
            14.3.6. GlaxoSmithKline Plc.
                     14.3.6.1. Overview
                     14.3.6.2. Financials
                     14.3.6.3. Recent Developments
                     14.3.6.4. Strategy
            14.3.7. Janssen Biotech, Inc.
                     14.3.7.1. Overview
                     14.3.7.2. Financials
                     14.3.7.3. Recent Developments
                     14.3.7.4. Strategy
            14.3.8. Merck & Co.
                     14.3.8.1. Overview
                     14.3.8.2. Financials
                     14.3.8.3. Recent Developments
                     14.3.8.4. Strategy
            14.3.9. Novartis AG
                     14.3.9.1. Overview
                     14.3.9.2. Financials
                     14.3.9.3. Recent Developments
                     14.3.9.4. Strategy
            14.3.10. Pfizer, Inc.
                     14.3.10.1. Overview
                     14.3.10.2. Financials
                     14.3.10.3. Recent Developments
                     14.3.10.4. Strategy
            14.3.11. Sanofi
                     14.3.11.1. Overview
                     14.3.11.2. Financials
                     14.3.11.3. Recent Developments
                     14.3.11.4. Strategy
            14.3.12. Spectrum Pharmaceuticals, Inc.
                     14.3.12.1. Overview
                     14.3.12.2. Financials
                     14.3.12.3. Recent Developments
                     14.3.12.4. Strategy
            14.3.13. Takeda Pharmaceuticals
                     14.3.13.1. Overview
                     14.3.13.2. Financials
                     14.3.13.3. Recent Developments
                     14.3.13.4. Strategy

List of Figures

Figure 1: Global Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2015–2024
Figure 2: Global Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2016 and 2024
Figure 3: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Monoclonal Antibodies, 2016–2024
Figure 4: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Immune Checkpoint Inhibitors, 2016–2024 
Figure 5: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Immune System Modulators, 2016–2024
Figure 6: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Cancer Vaccines, 2016–2024 
Figure 7: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Others, 2016–2024
Figure 8: Global Cancer Immunotherapy Market Attractiveness Analysis, by Therapy Type
Figure 9: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By PD-1/PD-L1 Type, 2016–2024
Figure 10: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By CTLA-4 Type, 2016–2024 
Figure 11: Global Cancer Immunotherapy Market Attractiveness Analysis, by Therapy Type (Immune Checkpoint Inhibitors)
Figure 12: Global Cancer Immunotherapy Market Value Share Analysis, by Therapeutic Area, 2016 and 2024
Figure 13: Global Cancer Immunotherapy Market Attractiveness Analysis, by Therapeutic Area
Figure 14: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Lung Cancer, 2016–2024
Figure 15: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Colorectal Cancer, 2016–2024 
Figure 16: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Breast Cancer, 2016–2024
Figure 17: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Prostate Cancer, 2016–2024
Figure 18: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Melanoma, 2016–2024
Figure 19: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Blood Cancers, 2016–2024 
Figure 20: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Other Cancers, 2016–2024
Figure 21: Global Cancer Immunotherapy Market Value Share Analysis, by End-User, 2016 and 2024
Figure 22: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Hospitals, 2016–2024
Figure 23: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By ASC’s, 2016–2024
Figure 24: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Cancer Research Institutes, 2016–2024
Figure 25: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Clinics, 2016–2024 
Figure 26: Global Cancer Immunotherapy Market Attractiveness Analysis, by End-User
Figure 27: Global Cancer Immunotherapy Market Value Share Analysis, by Region, 2016 and 2024
Figure 28: Global Cancer Immunotherapy Market Attractiveness Analysis, by Region
Figure 29: North America Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 30: North America Cancer Immunotherapy Market Attractiveness Analysis By Country
Figure 31: North America Market Value Share Analysis, by Therapy Type, 2016 and 2024
Figure 32: North America Market Value Share Analysis, by Therapeutic Area, 2016 and 2024
Figure 33: North America Market Value Share Analysis, by End-User, 2016 and 2024
Figure 34: North America Market Value Share Analysis, by Country, 2016 and 2024
Figure 35: U.S. Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 36: U.S. Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 37: Canada Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 38: Canada Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 39: North America Cancer Immunotherapy Market Attractiveness by Therapy Type
Figure 40: North America Cancer Immunotherapy Market Attractiveness by Therapeutic Area
Figure 41: North America Cancer Immunotherapy Market Attractiveness by End-User
Figure 42: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 43: Europe Cancer Immunotherapy Market Attractiveness Analysis by Country
Figure 44: Europe Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2016 and 2024
Figure 45: Europe Cancer Immunotherapy Market Value Share Analysis, by Therapeutic Area, 2016 and 2024
Figure 46: Europe Cancer Immunotherapy Market Value Share Analysis, by End-User, 2016 and 2024
Figure 47: Europe Cancer Immunotherapy Market Value Share Analysis, by Country, 2016 and 2024
Figure 48: Germany Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 49: Germany Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 50: U.K. Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 51: U.K. Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 52: France Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 53: France Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 54: Spain Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 55: Spain Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 56: Italy Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 57: Italy Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 58: Rest of Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 59: Rest of Europe Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 60: Europe Cancer Immunotherapy Market Attractiveness by Therapy Type
Figure 61: Europe Cancer Immunotherapy Market Attractiveness by Therapeutic Area 
Figure 62: Europe Cancer Immunotherapy Market Attractiveness by End-User
Figure 63: Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 64: Asia Pacific Cancer Immunotherapy Market Attractiveness Analysis, By Country
Figure 65: Asia Pacific Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2016 and 2024
Figure 66: Asia Pacific Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2016 and 2024
Figure 67: Asia Pacific Cancer Immunotherapy Market Value Share Analysis, by End-User, 2016 and 2024
Figure 68: Asia Pacific Cancer Immunotherapy Market Value Share Analysis, by Country, 2016 and 2024
Figure 69: Japan Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 70: Japan Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 71: China Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 72: China Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 73: India Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 74: India Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 75: Australia Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 76: Australia Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 77: New Zealand Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 78: New Zealand Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 79: Rest of Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 80: Rest of Asia Pacific Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 81: Asia Pacific Cancer Immunotherapy Market Attractiveness by Therapy Type
Figure 82: Asia Pacific Cancer Immunotherapy Market Attractiveness by Therapeutic Area
Figure 83: Asia Pacific Cancer Immunotherapy Market Attractiveness by End-User
Figure 84: Asia Pacific Cancer Immunotherapy Market Attractiveness by End-User
Figure 85: Latin America Cancer Immunotherapy Market Attractiveness Analysis by Country
Figure 86: Latin America Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2016 and 2024
Figure 87: Latin America Cancer Immunotherapy Market Value Share Analysis, by Therapeutic Area, 2016 and 2024
Figure 88: Latin America Cancer Immunotherapy Market Value Share Analysis, by End-User, 2016 and 2024
Figure 89: Latin America Cancer Immunotherapy Market Value Share Analysis, by Country, 2016 and 2024
Figure 90: Brazil Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 91: Brazil Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 92: Mexico Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 93: Mexico Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 94: Mexico Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 95: Rest of Latin America Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 96: Latin America Cancer Immunotherapy Market Attractiveness by Therapy Type
Figure 97: Latin America Cancer Immunotherapy Market Attractiveness by Therapeutic Area
Figure 98: Latin America Cancer Immunotherapy Market Attractiveness by End-User
Figure 99: Middle East & Africa Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 100: Middle East & Africa Cancer Immunotherapy Market Attractiveness Analysis by Country
Figure 101: Middle East & Africa Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2016 and 2024
Figure 102: Middle East & Africa Cancer Immunotherapy Market Value Share Analysis, by Therapeutic Area, 2016 and 2024
Figure 103: Middle East & Africa Cancer Immunotherapy Market Value Share Analysis, by End-User, 2016 and 2024
Figure 104: Middle East & Africa Cancer Immunotherapy Market Value Share Analysis, by End-User, 2016 and 2024
Figure 105: Saudi Arabia Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 106: Saudi Arabia Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 107: UAE Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 108: UAE Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 109: RSA Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 110: RSA Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 111: Rest of Middle East & Africa Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 112: Rest of Middle East & Africa Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 113: Middle East & Africa Cancer Immunotherapy Market Attractiveness by Therapy Type
Figure 114: Middle East & Africa Cancer Immunotherapy Market Attractiveness by Therapeutic Area
Figure 115: Middle East & Africa Cancer Immunotherapy Market Attractiveness by End-User

List of Tables

Table 1: Global Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type, 2016–2024
Table 2: Global Cancer Immunotherapy Market Size (US$ Mn) Forecast, By Therapy Type (Immune Checkpoint Inhibitors), 2016–2024
Table 3: Global Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapeutic Area, 2016–2024
Table 4: Global Cancer Immunotherapy Market Size (US$ Mn) Forecast, by End-User, 2016–2024
Table 5: Global Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Region, 2016–2024
Table 6: North America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type, 2016–2024
Table 7: North America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type (Immune Checkpoint Inhibitors), 2016–2024
Table 8: North America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapeutic Area, 2016–2024
Table 9: North America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by End-User, 2016–2024
Table 10: North America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 11: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type, 2016–2024
Table 12: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type (Immune Checkpoint Inhibitors), 2016–2024
Table 13: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapeutic Area, 2016–2024
Table 14: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, by End-User, 2016–2024
Table 15: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 16: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 17: Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type, 2016–2024
Table 18: Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type (Immune Checkpoint Inhibitors), 2016–2024
Table 19: Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapeutic Area, 2016–2024
Table 20: Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, by End-User, 2016–2024
Table 21: Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 22: Latin America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type, 2016–2024
Table 23: Latin America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type (Immune Checkpoint Inhibitors), 2016–2024
Table 24: Latin America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapeutic Area, 2016–2024
Table 25: Latin America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by End-User, 2016–2024
Table 26: Latin America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 27: Middle East & Africa Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type, 2016–2024
Table 28: Middle East & Africa Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type (Immune Checkpoint Inhibitors), 2016–2024
Table 29: Middle East & Africa Cancer Immunotherapy Market Size (US$ Mn) Forecast, by End-User, 2016–2024
Table 30: Middle East & Africa Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2016–2024

Global Cancer Immunotherapy Market: Overview 

The growing incidences of cancer and a need to treat them is the key driver of the global immunotherapy market. The number of deaths occurring due to cancer is increasing every year and has therefore forced government bodies to take initiatives for the improvement of the health conditions of people, by investing heavily in research and development and enabling innovation and advancements in technology so as to offer improved treatments. This has pushed the growth of the global cancer immunotherapy therapy. As immunotherapy therapy has a higher success rate and proven efficiency over conventional treatment methods for cancer, its demand is higher and therefore, the market is expected to witness a remarkable growth over the coming years. The treatment pipeline looks promising and is thus, expected to ensure a healthy growth of the market. 

The report offers forecasts of the overall cancer immunotherapy market over the global level as well as on regional levels. The estimated size of each of the segments and sub-segments has also been given in the report. Macroeconomic indicators, drivers, and restraints impacting the global cancer immunotherapy market have been included along with their impact on each region. Current challenges met by players in the cancer immunotherapy market have been elaborated on, thus giving a brief idea to readers and investors the problems they may encounter while investing in the competitive market. 

Global Cancer Immunotherapy Market: Trends and Drivers 

The global cancer immunotherapy market is expected to hold promising growth as there lies immense scope for improvement and development. The increasing number of clinical trials held particularly in immunotherapy is expected to boost the market’s growth. With the recognition from various medical bodies as the foremost line of therapy over conventional chemotherapy, cancer immunotherapy is estimated to hold immense potential and growth opportunity in the coming years. 

However, factors such as high attrition rates during product development phase are anticipated to restrict the growth of the market. Also, an overall lack of awareness about immunotherapy being a better treatment option will impede the growth of the market. The high cost of clinical trials poses a challenge for players in the market. With many types and subtypes of cancer, having a single mode of treatment method is impossible, increasing the attrition rates of new drugs and treatments. Only a handful of contenders in the pipeline pass through the phase III trials and the rest are considered to be inefficient. This is yet another challenge faced by players in the market. 

Global Cancer Immunotherapy Market: Segmentation 

On the basis of therapeutic area, the market is segmented into colorectal cancer, lung cancer, breast cancer, melanoma, prostate cancer, and blood cancer. By end users, the global cancer immunotherapy market is segmented into ASC’s (ambulatory surgical centers), hospitals, clinics, and cancer research centers. Hospitals are expected to be the leading segment in the market. On the basis of region, the market is segmented into North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa. Asia Pacific is poised to witness significant growth in the market.

Key Players Mentioned in this Report are: 

The report provides studies key players operating in the market. Some of the key players in the global cancer immunotherapy market are: F.Hoffmann-La Roche Ltd., AstraZenca Plc, Eli Lilly and Company, Amgen, Inc., Bristol-Myers Squibb Company, GlaxoSmithKline Plc., Novartis AG, Pfizer, Inc., Janssen Biotech, Inc., Merck & Co., Inc., Janssen Biotech, Inc., Merck & Co., Inc., Sanofi, Takeda Pharmaceuticals, and Spectrum Pharmaceuticals, Inc. 

The report segments the global cancer immunotherapy market as: 

By Geography: 

  • North America
  • Asia Pacific
  • Europe
  • Rest of the World 

This report gives you access to decisive data such as: 

  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for the coming years 

Key highlights of this report 

  • Overview of key market forces propelling and restraining market growth
  • Up-to-date analyses of market trends and technological improvements
  • Pin-point analyses of market competition dynamics to offer you a competitive edge
  • An analysis of strategies of major competitors
  • An array of graphics and SWOT analysis of major industry segments
  • Detailed analyses of industry trends
  • A well-defined technological growth map with an impact-analysis
  • Offers a clear understanding of the competitive landscape and key product segments


 
 
Back To Top